MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Summary

This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a screening tool and specific laboratory tests to help improve participants' ability to register to clinical trials throughout the course of their myeloid cancer (acute myeloid leukemia or myelodysplastic syndrome) treatment. This study involves testing patients' bone marrow and blood for certain biomarkers. A biomarker (sometimes called a marker) is any molecule in the body that can be measured. Doctors look at markers to learn what is happening in the body. Knowing about certain markers can give doctors more information about what is driving the cancer and how to treat it. Testing patients' bone marrow and blood will show doctors if patients have markers that specific drugs can target. The marker testing in this study will let doctors know if they can match patients with a treatment study (myeloMATCH clinical trial) that tests treatment for the type of cancer they have or continue standard of care treatment with their doctor on the Tier Advancement Pathway (TAP).

Conditions

• Acute Myeloid Leukemia
• Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm
• Acute Myeloid Leukemia Post Cytotoxic Therapy
• Acute Myeloid Leukemia, Myelodysplasia-Related
• Myelodysplastic Syndrome

Interventions

PROCEDURE

Allogeneic Hematopoietic Stem Cell Transplantation

Given IV

DRUG

Azacitidine

Given IV or SC

OTHER

Best Practice

Receive SOC treatment

PROCEDURE

Biopsy Procedure

Undergo biopsy

PROCEDURE

Biospecimen Collection

Undergo collection of blood, urine, and/or buccal swab samples

PROCEDURE

Bone Marrow Aspiration

Undergo bone marrow aspiration

PROCEDURE

Bone Marrow Biopsy

Undergo bone marrow biopsy

DRUG

Busulfan

Given IV

PROCEDURE

Chest Radiography

Undergo chest x-ray

PROCEDURE

Computed Tomography

Undergo CT

DRUG

Cytarabine

Given

DRUG

Daunorubicin Hydrochloride

Given IV

DRUG

Decitabine and Cedazuridine

Given PO

PROCEDURE

Echocardiography Test

Undergo ECHO

BIOLOGICAL

Emavusertib

Given PO

DRUG

Enasidenib

Given PO

BIOLOGICAL

Epoetin Alfa

Given SC

DRUG

Fludarabine

Given IV

DRUG

Gemtuzumab Ozogamicin

Given IV

DRUG

Gilteritinib

Given PO

DRUG

Liposome-encapsulated Daunorubicin-Cytarabine

Given IV

BIOLOGICAL

Luspatercept

Given SC

DRUG

Melphalan

Given IV

PROCEDURE

Multigated Acquisition Scan

Undergo MUGA

PROCEDURE

Mutation Carrier Screening

Undergo rapid genetic testing

DRUG

Olutasidenib

Given PO

DRUG

Placebo Administration

Given PO

PROCEDURE

Positron Emission Tomography

Undergo PET

RADIATION

Total-Body Irradiation

Undergo total body irradiation

DRUG

Venetoclax

Given PO

Sponsors & Collaborators

• National Cancer Institute (NCI)

  lead NIH

Principal Investigators

• Jerald P Radich · SWOG Cancer Research Network

Study Design

Allocation

NA

Purpose

SCREENING

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2024-06-18

Primary Completion

2029-05-15

Completion

2029-05-15

FDA Drug

Yes

Countries

• United States
• Canada
• Puerto Rico

Study Locations